Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017
Introduction: Diabetic Macular Edema (DME) is a manifestation of diabetic retinopathy and is the most common cause of vision loss in diabetics. The incidence of DME has a tendency to increase, concomitant with the prevalence of diabetes globally by more than 50% from 2000 to 2030. This study aims to...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Journal of Retina
2019-09-01
|
| Series: | IJRETINA (International Journal of Retina) |
| Online Access: | https://ijretina.com/index.php/ijretina/article/view/70 |
| _version_ | 1818911896017829888 |
|---|---|
| author | Andi Arus Victor Masniah Masniah Ari Djatikusumo Elvioza Elvioza Gitalisa Andayani Adriono Anggun Rama Yudantha Mario Marbungaran Hutapea |
| author_facet | Andi Arus Victor Masniah Masniah Ari Djatikusumo Elvioza Elvioza Gitalisa Andayani Adriono Anggun Rama Yudantha Mario Marbungaran Hutapea |
| author_sort | Andi Arus Victor |
| collection | DOAJ |
| description | Introduction: Diabetic Macular Edema (DME) is a manifestation of diabetic retinopathy and is the most common cause of vision loss in diabetics. The incidence of DME has a tendency to increase, concomitant with the prevalence of diabetes globally by more than 50% from 2000 to 2030. This study aims to evaluate the proportion of central macular thickness (CMT) improvement and visual acuity in DME patients treated with intravitreal bevacizumab (IVB) injection.
Methods: This study is a retrospective descriptive study. The study was conducted in the Department of Ophthalmology at RSUP Cipto Mangunkusumo (RSCM) Jakarta. Data were obtained from the medical records of all diabetic retinopathy patients with macular edema who were treated with IVB at RSCM Kirana Vitreoretina Polyclinic on January – December 2017.
Results: Of the 44 subjects, improvement in best corrected visual acuity (BCVA) occurred in 24 (54.54%) subjects at the first-month evaluation and 19 (43.18%) subjects at the third-month evaluation. CMT decreased in 37 (84.41%) subjects at the first-month evaluation and 35 (81.81%) subjects at the third-month evaluation.
Conclusion: Visual acuity improvement and central macular thickness reduction 3 months after IVB injection. These results strengthen IVB injection to be an alternative to adjuvant therapy in DME.
Keywords: Diabetic Macular Edema, Intravitreal Bevacizumab Injection |
| first_indexed | 2024-12-19T23:05:59Z |
| format | Article |
| id | doaj.art-6fc74c840d4b4568a865ccfa56cc0912 |
| institution | Directory Open Access Journal |
| issn | 2614-8684 2614-8536 |
| language | English |
| last_indexed | 2024-12-19T23:05:59Z |
| publishDate | 2019-09-01 |
| publisher | International Journal of Retina |
| record_format | Article |
| series | IJRETINA (International Journal of Retina) |
| spelling | doaj.art-6fc74c840d4b4568a865ccfa56cc09122022-12-21T20:02:23ZengInternational Journal of RetinaIJRETINA (International Journal of Retina)2614-86842614-85362019-09-012210.35479/ijretina.2019.vol002.iss002.7070Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017Andi Arus Victor0Masniah MasniahAri DjatikusumoElvioza ElviozaGitalisa Andayani AdrionoAnggun Rama YudanthaMario Marbungaran HutapeaFaculty of Medicine Universitas IndonesiaIntroduction: Diabetic Macular Edema (DME) is a manifestation of diabetic retinopathy and is the most common cause of vision loss in diabetics. The incidence of DME has a tendency to increase, concomitant with the prevalence of diabetes globally by more than 50% from 2000 to 2030. This study aims to evaluate the proportion of central macular thickness (CMT) improvement and visual acuity in DME patients treated with intravitreal bevacizumab (IVB) injection. Methods: This study is a retrospective descriptive study. The study was conducted in the Department of Ophthalmology at RSUP Cipto Mangunkusumo (RSCM) Jakarta. Data were obtained from the medical records of all diabetic retinopathy patients with macular edema who were treated with IVB at RSCM Kirana Vitreoretina Polyclinic on January – December 2017. Results: Of the 44 subjects, improvement in best corrected visual acuity (BCVA) occurred in 24 (54.54%) subjects at the first-month evaluation and 19 (43.18%) subjects at the third-month evaluation. CMT decreased in 37 (84.41%) subjects at the first-month evaluation and 35 (81.81%) subjects at the third-month evaluation. Conclusion: Visual acuity improvement and central macular thickness reduction 3 months after IVB injection. These results strengthen IVB injection to be an alternative to adjuvant therapy in DME. Keywords: Diabetic Macular Edema, Intravitreal Bevacizumab Injectionhttps://ijretina.com/index.php/ijretina/article/view/70 |
| spellingShingle | Andi Arus Victor Masniah Masniah Ari Djatikusumo Elvioza Elvioza Gitalisa Andayani Adriono Anggun Rama Yudantha Mario Marbungaran Hutapea Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017 IJRETINA (International Journal of Retina) |
| title | Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017 |
| title_full | Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017 |
| title_fullStr | Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017 |
| title_full_unstemmed | Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017 |
| title_short | Intravitreal Bevacizumab In Diabetic Macular Edema At RSUP Cipto Mangunkusumo in 2017 |
| title_sort | intravitreal bevacizumab in diabetic macular edema at rsup cipto mangunkusumo in 2017 |
| url | https://ijretina.com/index.php/ijretina/article/view/70 |
| work_keys_str_mv | AT andiarusvictor intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 AT masniahmasniah intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 AT aridjatikusumo intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 AT elviozaelvioza intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 AT gitalisaandayaniadriono intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 AT anggunramayudantha intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 AT mariomarbungaranhutapea intravitrealbevacizumabindiabeticmacularedemaatrsupciptomangunkusumoin2017 |